Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khawaja Shahzad

Psychiatry Toledo, OH Medical Doctor

NPI 1629193123 CMS profile 28657

2770 Centennial Rd, Toledo, OH 43617

Open in the dashboard

General payments

$7,378

445 records reported · program years 2019–2025

Research payments

$125

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khawaja Shahzad of Toledo, OH is reported in the CMS Open Payments database as having received $7,378 across 445 general payments and $125 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $888 37
2024 General $1,325 59
2023 General $1,128 59
2022 General $673 38
2021 General $793 50
2020 General $1,142 78
2019 General $1,429 124
2019 Research $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khawaja Shahzad
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Khawaja Shahzad were reported at $888. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Khawaja Shahzad Psychiatry median Middle half National median
2019 $1,429 $184 $59–$605 $163
2020 $1,142 $119 $36–$372 $114
2021 $793 $143 $43–$576 $132
2022 $673 $153 $50–$590 $149
2023 $1,128 $170 $56–$651 $160
2024 $1,325 $179 $57–$673 $164
2025 $888 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $1,148 79 payments
  2. Supernus Pharmaceuticals, Inc. $618 34 payments
  3. Axsome Therapeutics, Inc. $503 20 payments
  4. AbbVie, Inc. $428 24 payments
  5. Ironshore Pharmaceuticals Inc. $403 24 payments
  6. Janssen Scientific Affairs, LLC $400 2 payments
  7. Corium, Inc. $385 22 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $367 35 payments
  9. Sunovion Pharmaceuticals Inc. $351 32 payments
  10. Tris Pharma Inc $342 23 payments
  11. Other $2,434 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,960 441 payments
  2. Consulting Fee $400 2 payments
  3. Education $18 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI $761 59 payments
  2. SPRAVATO $633 15 payments
  3. QELBREE $552 32 payments
  4. Auvelity $503 20 payments
  5. Azstarys $385 22 payments
  6. LATUDA $351 32 payments
  7. ABILIFY MAINTENA $348 16 payments
  8. VRAYLAR $319 19 payments
  9. TRINTELLIX $228 15 payments
  10. BRINTELLIX $201 12 payments
  11. Other $4,256 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Indivior Inc. $125 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

229

Median for Psychiatry: 574

Drug cost

$45,406

Median for Psychiatry: $27,624

Branded share of claims

40.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 18 $35,357
Trintellix Vortioxetine Hydrobromide Brand 14 $7,876
Oxcarbazepine Generic 22 $590
Venlafaxine Hcl Er Venlafaxine Hcl Brand 16 $310
Bupropion Xl Bupropion Hcl Brand 21 $302
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 12 $243
Duloxetine Hcl Generic 22 $207
Lorazepam Generic 35 $137
Escitalopram Oxalate Generic 11 $124
Trazodone Hcl Generic 11 $83

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $237
$237 — —
SPRAVATO
  • Janssen Scientific Affairs, LLC $200
$200 — —
VRAYLAR
  • AbbVie, Inc. $189
$189 18 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $135
  • Lundbeck LLC $19
$154 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $145
$145 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record